Alpha-lipoic acid for diabetic peripheral neuropathy

To assess the effects of ALA as a disease-modifying agent in DPN, looking at clinical indicators and biomarkers of disease (symptoms, neuropathy scores, ulceration, quality of life, and neurophysiological parameters), and adverse events.

This is a protocol.

Share/Save